Harry Erba, MD, PhD

Articles

Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

August 25th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Dr. Erba on Unique Characteristics of CPX-351 in AML

August 22nd 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Dr. Erba on the FDA Approval of CPX-351 in AML

August 11th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Dr. Erba on FLT3 Inhibitors for the Treatment of AML

April 2nd 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).

Dr. Erba on BCR-ABL Ratio After Imatinib in CML

February 25th 2014

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Dr. Erba on Curative Therapy for Acute Myeloid Leukemia

May 22nd 2013

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses treating a patient with acute myeloid leukemia with curative intent.

Dr. Erba on the Diagnosis and Testing of Patients with CML

April 9th 2013

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, comments on the diagnosis and testing of a patient with chronic myeloid leukemia (CML).

Dr. Erba on Second-Generation TKIs for Chronic Phase CML

March 18th 2013

Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.

Dr. Erba on Azacitidine and Gemtuzumab Ozogamicin

January 23rd 2013

Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.

Dr. Erba on Treatment-Related Mortality Rates in AML

December 9th 2012

Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.

x